Important Notice for Shareholders of ESSA Pharma Inc.
The Gross Law Firm is reaching out to all stakeholders of ESSA Pharma Inc. (NASDAQ: EPIX) to provide critical information regarding an upcoming lead plaintiff deadline. As we aim to protect the rights of investors, it’s essential for shareholders to stay updated on this significant lawsuit.
Key Dates to Remember
Shareholders who purchased shares of EPIX within the specified class period are encouraged to connect with The Gross Law Firm for potential lead plaintiff appointments. While becoming a lead plaintiff is optional, participation in any recovery requires registration.
Class Period
The defined class period runs from December 12, 2023 through October 31, 2024. This period is crucial for investors who may have faced losses due to misleading information disseminated by the company.
Legal Allegations
The allegations outlined in the lawsuit assert that during the class period, ESSA Pharma issued misleading statements regarding the efficacy of its drug, masofaniten, particularly when used in conjunction with enzalutamide for treating prostate cancer. Concerns highlighted in the complaint suggest that:
- Masofaniten did not demonstrate a notable efficacy advantage over enzalutamide alone.
- The combination treatment was inadequately effective compared to disclosures made by company executives.
- The M-E Combination Study was unlikely to achieve its anticipated Phase 2 primary endpoint, which could have far-reaching implications.
- Such misrepresentations led to inflated stock prices that did not reflect the company’s actual performance and prospects.
Action Required by Shareholders
The deadline to register as a potential lead plaintiff is set for March 25, 2025. Shareholders affiliated with EPIX during the defined timeframe should act promptly to ensure their rights are protected. Visit the law firm’s registration page for more information and to submit your details.
What to Expect Next?
Upon registration, shareholders will gain access to a portfolio monitoring system that provides updates throughout the litigation process. The Gross Law Firm will keep you informed regarding the status and progress of the case from start to finish.
Why Choose The Gross Law Firm?
As a reputable class action law firm, The Gross Law Firm is dedicated to protecting investor rights and addressing wrongful conduct displayed by companies. They focus on recovering losses incurred by investors due to fraudulent practices and misleading company communications. Investors can trust the firm’s commitment to corporate accountability and transparency in business operations.
Contact Information
If you have inquiries or need assistance, reach out to The Gross Law Firm directly. Here are the contact details:
The Gross Law Firm
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the class period for ESSA Pharma Inc.?
The class period for ESSA Pharma Inc. runs from December 12, 2023, to October 31, 2024.
What are the allegations against ESSA Pharma?
The lawsuit alleges that the company provided misleading information regarding the effectiveness of its drug masofaniten in combination with enzalutamide.
How can I register as a lead plaintiff?
Shareholders can register by contacting The Gross Law Firm and submitting their information before the March 25, 2025 deadline.
Is there any cost to participate in this case?
No, there is no cost or obligation for investors to participate in the class action case.
Why is it important to act now?
Acting swiftly ensures your rights as an investor are protected and you are kept informed about any potential recovery.
